Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours-Reference-Cited by-同舟云学术

Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours

Published:2018-04 Issue:4 Volume:27 Page:1033-1040
ISSN:1052-3057
Container-title:Journal of Stroke and Cerebrovascular Diseases
language:en
Short-container-title:Journal of Stroke and Cerebrovascular Diseases

Author:

Deguchi Ichiro,Tanahashi Norio,Takao Masaki

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Neurology (clinical),Rehabilitation,Surgery

Reference15 articles.

1. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society;Minematsu;J Stroke Cerebrovasc Dis,2013

2. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS);Nakagawara;Stroke,2010

3. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register;Toyoda;Stroke,2009

4. Thrombolysis with low-dose tissue plasminogen activator 3-4.5 h after acute ischemic stroke in five hospital groups in Japan;Morihara;Transl Stroke Res,2016

5. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials;Emberson;Lancet,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical study of Edaravone Dexborneol combined with Tirofiban in treatment of Acute Cerebral Infarction;Pakistan Journal of Medical Sciences;2023-10-25

2. Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3–4.5 h;Frontiers in Neurology;2022-02-08

3. Elaborately Engineering a Self‐Indicating Dual‐Drug Nanoassembly for Site‐Specific Photothermal‐Potentiated Thrombus Penetration and Thrombolysis;Advanced Science;2021-11-21

4. THE IMPACT OF FULL-TIME STROKE FIRST-AID OF STROKE ON THE THROMBOLYSIS TIME AND PROGNOSIS OF PATIENTS WITH ACUTE CEREBRAL INFARCTION;ACTA MEDICA MEDITERR;2021

5. Automatic detection of multiple sclerosis lesions using Mask R‐CNN on magnetic resonance scans;IET Image Processing;2020-12